Cassava Sciences to Participate in Q&A Panel Discussion on Alzheimer’s Disease

Rhea-AI Summary

Cassava Sciences (Nasdaq: SAVA) is set to join a virtual panel on innovative treatment approaches for Alzheimer’s disease on May 26 at 11:00am Eastern Time. The discussion will be moderated by Jason McCarthy, PhD, from Maxim Group, featuring Remi Barbier, President & CEO of Cassava Sciences. Alzheimer's, affecting approximately 50 million people globally, is a progressive brain disorder without current drug therapies to halt its advancement. The annual global cost of dementia exceeds $1 trillion.

- Virtual Panel to be Held on Wednesday, May 26^th, 11:00am Eastern Time -

- Discussion to be Moderated by Jason McCarthy, PhD, Head of Biotechnology Research at Maxim Group -

AUSTIN, Texas, May 24, 2021 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced it will participate in a Q&A panel discussion focused on innovative treatment approaches for Alzheimer’s disease. Jason McCarthy, PhD, Head of Biotechnology Research Group and Senior Managing Director, Maxim Group, will moderate the discussion on Wednesday, May 26^th at 11:00am Eastern time.

Remi Barbier, President & CEO, will participate for Cassava Sciences. To RSVP for the Maxim Group/M-Vest Virtual Panel on Alzheimer’s Disease, please visit the event website, here.

About Alzheimer’s Disease
Alzheimer’s disease is a progressive brain disorder that destroys memory and thinking skills. Currently, there are no drug therapies to halt Alzheimer’s disease, much less reverse its course. As of 2020, there were approximately 50 million people worldwide living with dementia, a figure expected to increase to 150 million by 2050.¹ The annual global cost of dementia is now above $1 trillion, according to Alzheimer’s Disease International, a charitable organization.

About Cassava Sciences, Inc.
Cassava Sciences’ mission is to discover and develop innovations for chronic, neurodegenerative conditions. Over the past 10 years, Cassava Sciences has combined state-of-the-art technology with new insights in neurobiology to develop novel solutions for Alzheimer’s disease. For more information, please visit: https://www.CassavaSciences.com

About Maxim Group/M-Vest
Maxim Group LLC is a full-service investment banking, securities and wealth management firm headquartered in New York. M-Vest serves as a digital marketplace, focused on providing investors with the latest information on innovative emerging growth companies.

For More Information Contact:
Eric Schoen, Chief Financial Officer
eschoen@CassavaSciences.com
(512) 501-2450

¹ Alzheimer's Disease International, Dementia Statistics, available on-line and accessed May 23, 2021.

FAQ

What is the date and time of the Cassava Sciences virtual panel on Alzheimer's disease?

The Cassava Sciences virtual panel on Alzheimer's disease is scheduled for May 26 at 11:00am Eastern Time.

Who will moderate the Cassava Sciences panel discussion?

The panel discussion will be moderated by Jason McCarthy, PhD, Head of Biotechnology Research at Maxim Group.

Who from Cassava Sciences will participate in the panel?

Remi Barbier, the President & CEO of Cassava Sciences, will participate in the panel discussion.

Why is the Cassava Sciences panel important for Alzheimer's disease research?

The panel focuses on innovative treatment approaches for Alzheimer's disease, a condition affecting around 50 million people worldwide, with no current therapies to halt its progression.

What organization is linked with the panel discussion on Alzheimer's disease?

The panel is organized in collaboration with Maxim Group, which focuses on providing information about emerging growth companies.